CH5015765
CH5015765 is an orally available Hsp90 inhibitor bound to the N-terminal ATP binding site, with a dissociation constant of 3.4 nM, CH5015765 exerts antiproliferative activity against human cancer cell lines, with IC50 values of 0.46 μM for HCT116 colorectal cancer cells and 0.57 μM for NCI-N87 gastric cancer cells. CH5015765 can be used for the study of cancer[1][2].
Product Specifications
CAS Number
959766-47-3
UNSPSC
12352005
Target
HSP
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.01
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
NC1=NC(C2=C(Cl)C=C3C4=C2C=CC=C4COC3)=NC(SC)=N1
Molecular Formula
C16H13ClN4OS
Molecular Weight
344.82
References & Citations
[1]Atsushi Suda, et al. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors. Bioorg Med Chem Lett. 2012 Jan 15;22 (2) :1136-41. |[2]Suda A, et al. Design and synthesis of 2-amino-6- (1H,3H-benzo[de]isochromen-6-yl) -1,3,5-triazines as novel Hsp90 inhibitors. Bioorg Med Chem. 2014 Jan 15;22 (2) :892-905.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HSP90
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
